Health Affairs June 1, 2023
Diana Bowser, Robert Bohler, Margot Trotter Davis, Dominic Hodgkin, Richard G. Frank, Constance M. Horgan

The overdose and addiction crisis continues to intensify, taking the lives of more than 100,000 Americans in 2021. Despite strong evidence that the three Food and Drug Administration (FDA)-approved medications (buprenorphine, extended-release naltrexone, and methadone) for the treatment of opioid use disorder (OUD) reduce mortality and improve patient outcomes, it is estimated that only 13 percent of the 7.6 million Americans with this treatable illness receive evidence-based medication treatment. To help close this enormous treatment gap, the Substance Abuse and Mental Health Services Administration proposed new rules that are designed to increase access to and retention in medication treatment at opioid treatment programs (OTPs), which primarily consists of treating OUD with methadone. The proposed rules would allow more flexibility at...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: FDA, Govt Agencies, Insurance, Patient / Consumer, Payer, Provider
Related Articles:
Achieving Value-Based Care Through the Payvider Model
10 recent healthcare industry lawsuits, settlements - 7
STAT+: UnitedHealth pays its own physician groups considerably more than others, driving up consumer costs and its profits
AI could be ‘transformational’ for payers, experts say
Reforming HSAs To Expand Gig Workers’ Access To Affordable Health Care

Share This Article